ClinicalTrials.gg
RecruitingNCT06726785RLS-DRD2geneUpdated Sep 11, 2025

Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment

An observational study in Restless Leg Syndrome (RLS), sponsored by HBC Immunology Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by HBC Immunology Inc · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Planned enrollment
9th of 12
50 · median 72
Started
2025
with 3 others
Observational
12 of 107
1 open now
Primary completion
2025-12
later than 3 of 12 live
Registered
100th of 107
by date

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 9th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 100th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS). Similar studies in Parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into the dopaminergic gene regulation seen in RLS. The dopamine agonist drugs to be included in this study are: Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn), Bromocriptine (Parlodel). Specifically, the study will collect nasal swabs of participants partitioned into two groups, those who have not used a dopamine agonist or been on a dopamine agonist for less than 1 month compared to those who have been on the medication for 6 or more months. This research could provide insight into changes in dopaminergic gene expression associated with Augmentation Syndrome (AS) which occurs after long term dopamine agonist treatment in RLS patients.

03

Conditions studied

  • Restless Leg Syndrome (RLS)

Keywords

  • restless leg syndrome
  • RLS
  • neurological
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diagnosed with RLS and on Dopamine Agonist treatments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide
  • Clinical diagnosis of Restless Legs Syndrome (RLS)
  • On-going Treatment with a dopamine agonist

Exclusion criteria

Exclusion Criteria:

* Use of any medication that might affect nasal epithelial cell collection with a nasal swab

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. To analyze the effect of duration of dopamine agonist treatments for changes in dopaminergic genes expression using nasal epithelial cells.

    Gene expression will be measured and reported as the Fold change, which is the ratio of expression levels between the DRD2 experimental gene vs GAPDH housekeeping gene expression and reported as the Fold change which will indicate the magnitude of upregulation or downregulation of the DRD2 gene. A fold change \>= 2 will be used as the minimum baseline to indicate upregulation and a fold change \< = 1/2 will be used as the minimum baseline to indicate downregulation.

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2025, 5 months after the start.

Of 17 observational studies under Restless Legs Syndrome, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 70. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 10, 2024
StartActual
Jul 1, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Feb 27, 2026
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06726785
Lead sponsor
HBC Immunology Inc
Responsible party
Bomi Framroze (Principal Investigator, HBC Immunology Inc) — Principal investigator
First posted
Dec 10, 2024
Start date
Jul 1, 2025
Primary completion
Dec 30, 2025 (estimated)
Completion
Feb 27, 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Bomi Framroze, PhD
Contact
bomi.framroze@hbcimmunology.com
6502068006

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion